# A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma

> **NCT02773030** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Celgene** · enrollment: 466 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** CC-220
- **DRUG:** Dexamethasone
- **DRUG:** Daratumumab
- **DRUG:** Bortezomib
- **DRUG:** Carfilzomib
- **DRUG:** Daratumumab - 16mg/kg
- **DRUG:** Bortezomib (BTZ)
- **DRUG:** Daratumumab- 1800mg

## Key facts

- **NCT ID:** NCT02773030
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2016-10-14
- **Primary completion:** 2024-05-09
- **Final completion:** 2028-07-28
- **Target enrollment:** 466 (ACTUAL)
- **Last updated:** 2026-03-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02773030

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02773030, "A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02773030. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*